Verve Therapeutics Inc. (VERV)
Verve Therapeutics Statistics
Share Statistics
Verve Therapeutics has 84.66M shares outstanding. The number of shares has increased by 7.78% in one year.
| Shares Outstanding | 84.66M |
| Shares Change (YoY) | 7.78% |
| Shares Change (QoQ) | 0.05% |
| Owned by Institutions (%) | 89.26% |
| Shares Floating | 66.18M |
| Failed to Deliver (FTD) Shares | 18 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 14.79M, so 17.47% of the outstanding shares have been sold short.
| Short Interest | 14.79M |
| Short % of Shares Out | 17.47% |
| Short % of Float | 23.43% |
| Short Ratio (days to cover) | 10.17 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -2.61. Verve Therapeutics's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -2.61 |
| PS Ratio | 0 |
| Forward PS | 39.3 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Verve Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.65, with a Debt / Equity ratio of 0.14.
| Current Ratio | 12.65 |
| Quick Ratio | 12.65 |
| Debt / Equity | 0.14 |
| Total Debt / Capitalization | 12.42 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.4% and return on capital (ROIC) is -40.52%.
| Return on Equity (ROE) | -0.4% |
| Return on Assets (ROA) | -0.31% |
| Return on Capital (ROIC) | -40.52% |
| Revenue Per Employee | 126.79K |
| Profits Per Employee | -779.25K |
| Employee Count | 255 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -349K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -61.26% in the last 52 weeks. The beta is 1.78, so Verve Therapeutics's price volatility has been higher than the market average.
| Beta | 1.78 |
| 52-Week Price Change | -61.26% |
| 50-Day Moving Average | 6.8 |
| 200-Day Moving Average | 5.95 |
| Relative Strength Index (RSI) | 39.15 |
| Average Volume (20 Days) | 1.58M |
Income Statement
In the last 12 months, Verve Therapeutics had revenue of 32.33M and earned -198.71M in profits. Earnings per share was -2.35.
| Revenue | 32.33M |
| Gross Profit | 32.33M |
| Operating Income | -228.66M |
| Net Income | -198.71M |
| EBITDA | -228.66M |
| EBIT | -228.66M |
| Earnings Per Share (EPS) | -2.35 |
Balance Sheet
The company has 172.56M in cash and 69.98M in debt, giving a net cash position of 102.58M.
| Cash & Cash Equivalents | 172.56M |
| Total Debt | 69.98M |
| Net Cash | 102.58M |
| Retained Earnings | -743.01M |
| Total Assets | 663.91M |
| Working Capital | 513.82M |
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0.
| Operating Cash Flow | 0 |
| Capital Expenditures | 0 |
| Free Cash Flow | 0 |
| FCF Per Share | 0 |
Margins
Gross margin is 100%, with operating and profit margins of -707.23% and -614.59%.
| Gross Margin | 100% |
| Operating Margin | -707.23% |
| Pretax Margin | -613.51% |
| Profit Margin | -614.59% |
| EBITDA Margin | -707.23% |
| EBIT Margin | -707.23% |
| FCF Margin | n/a |
Dividends & Yields
VERV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -37.24% |
| FCF Yield | 0% |
Analyst Forecast
The average price target for VERV is $24.5, which is 288.3% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $24.5 |
| Price Target Difference | 288.3% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 0.44 |
| Piotroski F-Score | 3 |